Physician profile
Heather Wright
NPI 1538768866
$1,889.12
in general payments reported to CMS, 2019-2025
25 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $494 · 2023: $658 · 2024: $555 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,395.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $327.82 | 2022-2024 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.29 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $211.67 | 2022-2024 | Rexulti, Abilify Maintena |
| Abbvie INC. | $156.39 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $123.35 | 2022-2025 | Farxiga, Breztri, Fasenra |
| Lilly USA, LLC | $117.60 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Lundbeck LLC | $114.38 | 2022-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.16 | 2022-2025 | Synjardy, Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $80.11 | 2022-2024 | |
| Axonics, INC. | $79.28 | 2023 | Axonics |
| Shield Therapeutics INC | $58.93 | 2023-2025 | Accrufer |
| Amgen INC. | $35.84 | 2022-2023 | Otezla, Repatha |
| Idorsia Pharmaceuticals US INC | $34.89 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $34.12 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $27.98 | 2025 | Dupixent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $24.80 | 2025 | |
| Dexcom, INC. | $22.15 | 2023 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $18.93 | 2024 | Nexletol |
| Verona Pharma, INC. | $18.11 | 2025 | Ohtuvayre |
| Paratek Pharmaceuticals, INC. | $17.18 | 2024 | Nuzyra |
| Daiichi Sankyo INC. | $17.00 | 2024 | Injectafer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.13 | 2024 | Lifevest |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.62 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.79 | 2022 | |
| Medtronic, INC. | $14.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.